BeiGene
BGNE
$184.71
Share price
0.49%
Change (1 day)
33.46%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Total debt
Total debt on the balance sheet as of September 2024 : $1.10 Billion USD
According to BeiGene 's latest financial reports the company's total debt is $1.10 Billion USD. A company’s total debt is the sum of all current and non-current debts.
BeiGene - Total debt on balance sheet (from 2014 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.93 B | 55.89% |
| 2022-12-31 | $0.59 B | -14.1% |
| 2021-12-31 | $0.69 B | 23.61% |
| 2020-12-31 | $0.56 B | 102.62% |
| 2019-12-31 | $0.27 B | 39.79% |
| 2018-12-31 | $0.19 B | 20.45% |
| 2017-12-31 | $0.16 B | 852.99% |
| 2016-12-31 | $17.28 M | -16.85% |
| 2015-12-31 | $20.78 M | 50.21% |
| 2014-12-31 | $13.83 M | -49.43% |
| 2013-12-31 | $27.36 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 | N/A | N/A | 🇺🇸 USA |
 | $0.50 B | -54.20% | 🇺🇸 USA |